Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
Leading Pharmaceutical company[1]Alkem Laboratories holds a4.1% market sharein the Indian domestic formulation market as of 9M FY25, making it the 5th largest pharmaceutical company in India. The company maintains its#1 positionin anti-infectives and has a strong presence in gastrointestinal, pain management, vitamins, minerals, and nutrients segments while also expanding in chronic therapies like neurology, cardiology, and diabetology.
| S.No. | Name | Current Price (Rs.) | Price to Earning | Market Capitalization (Rs.Cr.) | Dividend yield (%) | Net Profit latest quarter (Rs.Cr.) | YOY Quarterly profit growth (%) | Sales latest quarter (Rs.Cr.) | YOY Quarterly sales growth (%) | Return on capital employed (%) | Sales (Rs.Cr.) | OPM (%) | Profit after tax (Rs.Cr.) | Profit after tax latest quarter (Rs.Cr.) | Price to book value | Return on assets (%) | Debt to equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Sun Pharma.Inds. | 1782.60 | 37.05 | 427717.60 | 0.90 | 3124.95 | 2.56 | 14478.31 | 8.93 | 20.21 | 54964.01 | 30.12 | 11543.96 | 3117.95 | 5.50 | 12.97 | 0.07 |
| 2. | Divi's Lab. | 6650.70 | 71.03 | 176510.01 | 0.45 | 689.00 | 35.10 | 2715.00 | 16.12 | 20.44 | 10029.00 | 32.37 | 2485.00 | 689.00 | 11.45 | 13.53 | 0.01 |
| 3. | Torrent Pharma. | 4091.25 | 63.92 | 138464.73 | 0.78 | 591.00 | 32.49 | 3302.00 | 14.30 | 27.05 | 12248.00 | 32.60 | 2166.53 | 600.17 | 16.39 | 13.26 | 0.33 |
| 4. | Cipla | 1467.30 | 21.79 | 118559.13 | 0.89 | 1353.37 | 3.73 | 7589.44 | 7.64 | 22.72 | 28349.57 | 25.40 | 5441.14 | 1351.17 | 3.60 | 14.72 | 0.01 |
| 5. | Dr Reddy's Labs | 1242.60 | 17.97 | 103731.81 | 0.64 | 1336.80 | 7.28 | 8828.30 | 9.83 | 22.69 | 34310.00 | 24.64 | 5772.20 | 1347.10 | 2.88 | 12.95 | 0.16 |
| 6. | Lupin | 2213.55 | 23.35 | 101008.98 | 0.54 | 1484.83 | 73.34 | 7047.51 | 24.23 | 21.30 | 24750.69 | 27.25 | 4324.63 | 1477.92 | 5.15 | 12.41 | 0.32 |
| 7. | Mankind Pharma | 2305.00 | 54.39 | 95107.00 | 0.04 | 520.18 | -22.00 | 3697.16 | 20.77 | 15.98 | 13545.67 | 24.12 | 1748.55 | 511.51 | 6.22 | 8.89 | 0.55 |
| 8. | Alkem Lab | 5785.60 | 30.96 | 69215.31 | 0.77 | 786.73 | 12.75 | 2542.03 | 7.95 | 19.53 | 9245.97 | 25.37 | 2236.04 | 723.66 | 5.06 | 15.37 | 0.06 |
| – | Median: 150 Co. | 410.27 | 30.96 | 1755.85 | 0.11 | 13.03 | 12.32 | 157.2 | 10.56 | 14.98 | 582.87 | 15.96 | 44.55 | 13.73 | 3.15 | 8.6 | 0.22 |
Standalone figures in ₹ crores
| Dec 2022 | Dec 2023 | Dec 2024 | Jun 2023 | Jun 2024 | Jun 2025 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 2,297 | 2,009 | 2,287 | 2,253 | 2,127 | 2,372 | 2,238 | 2,365 | 2,045 | 2,461 | 2,635 | 2,355 | 2,542 |
Expenses | 1,841 | 1,517 | 1,629 | 1,919 | 1,566 | 1,752 | 1,906 | 1,958 | 1,748 | 2,056 | 1,980 | 1,714 | 1,771 |
Operating Profit | 456 | 492 | 658 | 334 | 561 | 620 | 332 | 408 | 297 | 406 | 655 | 640 | 771 |
Other Income | 61 | 93 | 216 | 65 | 144 | 165 | 77 | 71 | 163 | 74 | 62 | 176 | 164 |
Profit before tax | 436 | 508 | 785 | 319 | 621 | 714 | 330 | 389 | 351 | 402 | 639 | 738 | 864 |
Tax % | 11% | 1% | 8% | 15% | 6% | 8% | 23% | 16% | 21% | 13% | -1% | 5% | 9% |
Net Profit | 389 | 504 | 723 | 271 | 583 | 656 | 255 | 325 | 277 | 351 | 647 | 698 | 787 |
EPS in Rs | 32.53 | 42.17 | 60.48 | 22.70 | 48.78 | 54.88 | 21.31 | 27.18 | 23.16 | 29.33 | 54.07 | 58.34 | 65.80 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 2,660 | 3,072 | 3,911 | 4,548 | 5,281 | 5,714 | 6,677 | 7,220 | 8,830 | 9,055 | 7,964 | 8,813 | 9,246 |
Expenses | 2,261 | 2,722 | 3,180 | 3,668 | 4,308 | 4,667 | 5,209 | 5,268 | 7,018 | 7,665 | 6,290 | 6,657 | 6,900 |
Operating Profit | 399 | 350 | 731 | 880 | 973 | 1,048 | 1,468 | 1,951 | 1,812 | 1,389 | 1,674 | 2,156 | 2,346 |
Other Income | 164 | 177 | 240 | 115 | 101 | 66 | 96 | 175 | 199 | 254 | 426 | 698 | 708 |
Interest | 84 | 73 | 59 | 24 | 32 | 28 | 39 | 43 | 38 | 86 | 80 | 76 | 63 |
Depreciation | 43 | 60 | 74 | 76 | 108 | 141 | 187 | 199 | 219 | 230 | 239 | 284 | 277 |
Profit before tax | 436 | 395 | 839 | 894 | 934 | 944 | 1,338 | 1,884 | 1,753 | 1,327 | 1,781 | 2,495 | 2,714 |
Net Profit | 440 | 368 | 700 | 883 | 716 | 800 | 1,264 | 1,685 | 1,541 | 1,134 | 1,747 | 2,281 | 2,443 |
EPS in Rs | 368.17 | 30.75 | 58.56 | 73.86 | 59.87 | 66.90 | 105.75 | 140.93 | 128.90 | 94.88 | 146.13 | 190.77 | 204.32 |
Dividend Payout % | 5% | 13% | 22% | 20% | 22% | 24% | 24% | 21% | 26% | 53% | 27% | 24% | – |
Standalone figures in ₹ crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 12 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
Reserves | 2,703 | 3,077 | 3,576 | 4,369 | 4,861 | 5,441 | 6,257 | 7,602 | 8,720 | 9,326 | 10,531 | 12,298 | 13,641 |
Borrowings | 947 | 1,103 | 380 | 368 | 548 | 503 | 1,209 | 1,384 | 2,294 | 1,182 | 1,005 | 439 | 874 |
Other Liabilities | 540 | 657 | 843 | 1,137 | 1,381 | 1,324 | 1,616 | 1,763 | 2,132 | 2,200 | 2,478 | 2,835 | 2,917 |
Total Liabilities | 4,202 | 4,861 | 4,822 | 5,898 | 6,814 | 7,292 | 9,106 | 10,773 | 13,169 | 12,731 | 14,038 | 15,596 | 17,455 |
Fixed Assets | 909 | 870 | 875 | 1,126 | 1,471 | 1,606 | 1,837 | 1,758 | 1,882 | 1,825 | 1,782 | 1,591 | 1,601 |
Gross Block | 909 | 1,156 | 945 | 1,263 | 1,714 | 1,973 | 2,352 | 2,482 | 2,960 | 2,932 | 3,144 | 3,083 | – |
Accumulated Depreciation | 0 | 286 | 70 | 137 | 243 | 367 | 515 | 724 | 1,078 | 1,107 | 1,362 | 1,492 | – |
CWIP | 0 | 96 | 147 | 218 | 299 | 382 | 314 | 323 | 232 | 229 | 91 | 76 | 73 |
Investments | 940 | 1,071 | 1,158 | 1,518 | 1,544 | 1,696 | 1,956 | 2,152 | 2,529 | 3,006 | 2,829 | 4,407 | 5,380 |
Other Assets | 2,352 | 2,824 | 2,644 | 3,037 | 3,500 | 3,609 | 4,999 | 6,539 | 8,526 | 7,672 | 9,336 | 9,521 | 10,402 |
Total Assets | 4,202 | 4,861 | 4,822 | 5,898 | 6,814 | 7,292 | 9,106 | 10,773 | 13,169 | 12,731 | 14,038 | 15,596 | 17,455 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operating Activity | 264 | 242 | 630 | 499 | 318 | 745 | 682 | 1,324 | 1,299 | 1,437 | 1,687 | 2,189 |
Cash from Investing Activity | 119 | -260 | 311 | -362 | -273 | -313 | -995 | -1,121 | -1,669 | 197 | -866 | -1,007 |
Cash from Financing Activity | -395 | 26 | -958 | -125 | -60 | -276 | 173 | -209 | 437 | -1,711 | -959 | -1,037 |
Net Cash Flow | -12 | 8 | -17 | 13 | -15 | 156 | -141 | -5 | 67 | -77 | -138 | 145 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 40 | 45 | 45 | 51 | 60 | 62 | 85 | 79 | 73 | 71 | 80 | 65 |
Inventory Days | 161 | 143 | 139 | 175 | 180 | 159 | 156 | 207 | 202 | 164 | 257 | 196 |
Days Payable | 88 | 90 | 110 | 139 | 144 | 121 | 116 | 131 | 114 | 103 | 219 | 188 |
Cash Conversion Cycle | 113 | 97 | 74 | 86 | 97 | 100 | 125 | 155 | 162 | 133 | 119 | 72 |
Working Capital Days | -48 | -62 | 12 | 29 | 43 | 51 | 39 | 45 | 13 | 50 | 171 | 128 |
ROCE % | 15% | 11% | 22% | 21% | 19% | 17% | 20% | 23% | 18% | 13% | 16% | 20% |
Direct from BSE filings, auto-summarised
External media mentions & references
Editorial & research coverage
Nov 2025
Aug 2025
Jun 2025
Mar 2025
Feb 2025
Nov 2024
Sep 2024
Aug 2024
Jun 2024
Feb 2024
Nov 2023
Aug 2023
Aug 2023
May 2023
Feb 2023
Nov 2022
Aug 2022
May 2022
Feb 2022
Nov 2021
Aug 2021
May 2021
Feb 2021
Nov 2020
Aug 2020
Aug 2020
Jun 2020
Jun 2020
Feb 2020
Nov 2019
Aug 2019
May 2019
Feb 2019
Oct 2018
Jul 2018
May 2018
Feb 2018
Feb 2018
Nov 2017
Aug 2017
May 2017
Jan 2017
Nov 2016
Aug 2016
May 2016
Feb 2016
Stock Analysis
Alkem Laboratories Limited is a leading pharmaceutical company with global operations, specializing in the development, manufacturing, and sale of pharmaceutical and nutraceutical products.
Key growth triggers include Alkem's strong market position in India (#1 in anti-infectives), expansion into chronic therapies, increasing international sales (especially US), new product launches (Pertuza, DSS, Renocia), strategic investment in Enzene Biosciences for biosimilars, and ventures into MedTech.
Currently no data available for Order Book.
Alkem Laboratories faces multiple Goods and Services Tax (GST) demand orders and penalties from various tax authorities across India. The company disputes these demands and plans to contest them, although their recurrence remains a concern.
The company regularly engages with investors and analysts, with recent meetings scheduled throughout late 2025. Key dates include the announcement of Q2 and H1 FY26 financial results on November 13, 2025, and the AGM on August 25, 2025.
Corporate Announcements
